Ignite Creation Date:
2024-05-05 @ 7:03 PM
Last Modification Date:
2024-10-26 @ 9:40 AM
Study NCT ID:
NCT00590785
Status:
COMPLETED
Last Update Posted:
2017-08-25
First Post:
2007-12-26
Brief Title:
Phase III Comparison of Adjuvant Chemotherapy WHigh-Dose Cyclophosphamide Plus Doxorubicin AC vs Sequential Doxorubicin Fol by Cyclophosphamide A-C in High Risk Breast Cancer Patients With 0-3 Positive Nodes Intergroup CALGB 9394
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase III Comparison of Adjuvant Chemotherapy WHigh-Dose Cyclophosphamide Plus Doxorubicin AC vs Sequential Doxorubicin Fol by Cyclophosphamide A-C in High Risk Breast Cancer Patients With 0-3 Positive Nodes Intergroup CALGB 9394
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare disease-free survival DFS overall survival s and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes treated with adjuvant high-dose chemotherapy with doxorubicin plus cyclophosphamide AC versus high-dose sequential chemotherapy with doxorubicin followed by cyclophosphamide A--C
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CALGB 9394 | None | None | None |
| INT 0137 | None | None | None |